Parexel Announces Strategic Functional Service Provider Relationship With Eli Lilly and Company for Clinical Development in Asia/Pacific Region
PAREXEL International Corporation announced the establishment of a strategic functional service provider relationship with Eli Lilly and Company, a global pharmaceutical company, to support study start-up and site monitoring of clinical trials throughout the Asia/Pacific region. PAREXEL will assist Lilly in bringing greater efficiencies to its clinical research studies to help meet Lilly's development and commercialization goals.
Through the agreement, Lilly will access PAREXEL's experience in Asia and Australia for study start-up and site monitoring. The collaboration will allow Lilly to focus on its relationships with investigators and regulators and increase its flexibility, productivity and efficiency. The strategic partnership with PAREXEL enables Lilly to more effectively allocate studies and apply necessary resources to meet patient and portfolio needs.
"We are constantly evaluating how we can increase our flexibility and focus internal efforts on our core capabilities," said Jeff Kasher, Ph.D., Vice President of Global Clinical Development, Eli Lilly and Company. "This strategic agreement enables us to leverage PAREXEL's expertise in clinical trial monitoring and site start-up services throughout the Asia/Pacific region, which will increase our ability to speed innovative medicines to patients."
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
